Research programme: cyclosporin-based mitochondrial protective therapeutics - NeuroVive/A1M Pharma
Latest Information Update: 01 Apr 2014
At a glance
- Originator A1M Pharma AB; NeuroVive Pharmaceutical
- Class Ciclosporins
- Mechanism of Action Calcineurin inhibitors; Cyclophilin D inhibitors; Free radical inhibitors; Immunosuppressants; Mitochondrial permeability transition pore inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Research Mitochondrial disorders
Most Recent Events
- 25 Mar 2014 Early research in Mitochondrial disorders in Sweden (unspecified route)